Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer

Molecular Cancer Therapeutics
Chrysiis MichaloglouSabina C Cosulich

Abstract

The cyclin dependent kinase (CDK)-retinoblastoma (RB)-E2F pathway plays a critical role in the control of cell cycle in estrogen receptor-positive (ER+) breast cancer. Small-molecule inhibitors of CDK4/6 have shown promise in this tumor type in combination with hormonal therapies, reflecting the particular dependence of this subtype of cancer on cyclin D1 and E2F transcription factors. mTOR inhibitors have also shown potential in clinical trials in this disease setting. Recent data have suggested cooperation between the PI3K/mTOR pathway and CDK4/6 inhibition in preventing early adaptation and eliciting growth arrest, but the mechanisms of the interplay between these pathways have not been fully elucidated. Here we show that profound and durable inhibition of ER+ breast cancer growth is likely to require multiple hits on E2F-mediated transcription. We demonstrate that inhibition of mTORC1/2 does not affect ER function directly, but does cause a decrease in cyclin D1 protein, RB phosphorylation, and E2F-mediated transcription. Combination of an mTORC1/2 inhibitor with a CDK4/6 inhibitor results in more profound effects on E2F-dependent transcription, which translates into more durable growth arrest and a delay in the onset of re...Continue Reading

References

Oct 3, 2006·Nature Genetics·Jason S CarrollMyles Brown
Sep 19, 2008·Genome Biology·Yong ZhangX Shirley Liu
Dec 30, 2008·The Journal of Biological Chemistry·Rachel L YamnikMarina K Holz
Mar 6, 2009·Genome Biology·Ben LangmeadSteven L Salzberg
Dec 15, 2010·Nature Genetics·Antoni HurtadoJason S Carroll
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Jul 19, 2013·Biochemical Society Transactions·Jessica J HowellBrendan D Manning
Feb 25, 2014·Future Oncology·Saranya ChumsriAngela Brodie
Jul 9, 2014·Cancer Cell·Sadhna R VoraJeffrey A Engelman
Jul 18, 2014·Nature Reviews. Cancer·Pedro A Pérez-ManceraMasashi Narita
Sep 23, 2014·Seminars in Cell & Developmental Biology·Kezhen Huang, Diane C Fingar
Aug 10, 2015·Methods in Molecular Biology·Ingrid Thurlings, Alain de Bruin
Oct 1, 2015·Nature Cell Biology·Kosuke Tomimatsu, Masashi Narita
Oct 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N HortobagyiJosé Baselga
Dec 15, 2015·Cancer Discovery·Charles J SherrGeoffrey I Shapiro
Feb 7, 2016·Aging·Hannah E WaltersLynne S Cox
Mar 1, 2016·Oncogene·J JohnsonR Bernards
Mar 30, 2016·Cancer Research·Maria Teresa Herrera-AbreuVioleta Serra
Apr 1, 2016·Nature Reviews. Clinical Oncology·Ben O'LearyNicholas C Turner
May 31, 2016·Molecular Cell·Jinfang ZhangWenyi Wei
Oct 19, 2016·Molecular Biology Reports·Menderes Yusuf TerziBulent Gogebakan
Nov 3, 2016·The New England Journal of Medicine·Gabriel N HortobagyiJoyce O'Shaughnessy
Jan 28, 2017·Nature Reviews. Cancer·Tobias Otto, Piotr Sicinski
Feb 9, 2017·Journal of Cancer Research and Therapeutics·R Priyadharsini Palanisamy

❮ Previous
Next ❯

Citations

Nov 28, 2018·International Journal of Cancer. Journal International Du Cancer·Kamal PandeyYong Wha Moon
Feb 27, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas C TurnerMassimo Cristofanilli
Nov 6, 2018·Endocrine-related Cancer·Neil PortmanC Elizabeth Caldon
Sep 5, 2019·Cells·João M A DelouHelena L Borges
Nov 2, 2019·Acta Oncologica·Lubaid SalehIngunn Holen
Mar 27, 2020·Medical Sciences : Open Access Journal·Ugo TestaElvira Pelosi
Jun 14, 2020·Signal Transduction and Targeted Therapy·Ling ChenYongguang Tao
Jun 7, 2020·Acta Pharmacologica Sinica·Xia-Qing XuLing Ding
Apr 30, 2020·Nature Reviews. Immunology·Giulia PetroniLorenzo Galluzzi
Mar 19, 2020·International Journal of Molecular Sciences·Lei DingQinghua Cui
Jul 14, 2020·The Journal of Clinical Investigation·Matt R PaulLewis A Chodosh
Aug 10, 2019·Cancer Research·Laia Martínez-CarreresLluis Fajas
Aug 28, 2019·Molecular Cancer Therapeutics·William B KietzmanAnna T Riegel
Aug 5, 2020·Molecular Cancer Therapeutics·Joy M GaryBeverly A Mock
Sep 4, 2019·Bioorganic & Medicinal Chemistry Letters·Concepción Sánchez-MartínezAlfonso de Dios
Apr 15, 2020·Cancer Cell·Mónica Álvarez-Fernández, Marcos Malumbres
Sep 3, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Chia-Hao KueiYuan-Feng Lin
Jan 8, 2021·Molecular Biology Reports·Georgia GomatouElias Kotteas
Dec 29, 2020·Frontiers in Pharmacology·Zhen LiCeshi Chen
Feb 9, 2020·Biochimica Et Biophysica Acta. Molecular Basis of Disease·Lucia C Leal-Esteban, Lluis Fajas
Aug 1, 2018·Trends in Cell Biology·Shom GoelJean J Zhao
Nov 11, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Preeti NarayanJulia A Beaver
Apr 2, 2021·Frontiers in Pharmacology·Chao DongCeshi Chen
Apr 4, 2021·The Breast : Official Journal of the European Society of Mastology·Debora BasileFabio Puglisi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.